- Details
- (Length of Conversation: 13 min) Charles Ryan and Fred Saad discuss the data results in patients with mCRPC from a combined therapeutic approach with abiraterone and apalutamide. They discuss the rationale and theory behind these results. Later they move to discuss the quality of life analysis for patients with CRPC. A review of the SPARTAN trial and the optimistic results from his work. Biographi...
|
- Details
- (Length of Discussion: 21 min) Russell Szmulewitz talks with Alicia Morgans about a trial that evaluated abiraterone with food and how that might affect relative patient outcomes, such as PSA. This study sought to test the hypothesis that low-dose Abiraterone acetate (AA) (LOW; 250 mg with a low-fat meal) would have comparable activity to standard dosed AA (STD; 1,000 mg fasting) in patients with...
|
- Details
- (Length of Conversation: 9 min) Fred Saad and Charles Ryan discuss the Movember Foundation sponsored, INTense Exercise foR surVivAL Among Men With Metastatic Castrate-Resistant Prostate Cancer Study (INTERVAL). This is a randomized phase 3 study of exercise in men with metastatic castrate-resistant prostate cancer (mCRPC). The objective of the study is to determine if high intensity aerobic and re...
|
- Details
- (Length of presentation: 17 min) Alicia Morgans, MD discusses the UPWARD Study with Susan Slovin, MD, PhD. A study Dr. Slovin was a part of conducting to answer the question “Are seizure rates affected by treatment with enzalutamide in patients with metastatic castration-resistant prostate cancer who have seizure risk factors?” Dr. Slovin discusses with Dr. Morgans the reasons for conducting the U...
|
- Details
- Sequencing and Combining CRPC Therapies: What Does the Future Hold? Presentation from the 2017 Annual LUGPA meeting in Chicago, IL (Length of Presentation: 21 min) Dr. Charles Ryan provides a comprehensive overview of CRPC including the natural history of prostate cancer and the many sequences that exist in the treatment of the disease. Dr. Ryan states that CRPC is a broad-spectrum condition so it...
|
- Details
- (Length of lecture ~ 36 minutes) Alicia Morgans hosts a discussion with David Penson, Charles Ryan and Neal Shore regarding impacts of LATITUDE and STAMPEDE data from a urologist and urologic oncologists perspective, taking in to account the recently updated data from the CHAARTED trial. Specifically, discussed was treating patients that have high-volume, aggressive metastatic prostate cancer that...
|
- Details
- (Length of discussion ~ 27 minutes) Charles Ryan hosts a discussion with Alicia Morgans and Christopher Sweeney regarding data from the LATITUDE, STAMPEDE and CHAARTED trials, and the survivor endpoints for patients receiving initial androgen deprivation therapy (ADT) for metastatic prostate cancer. Specifically, discussed is the interface of these three very important studies and the many treatme...
|
- Details
- Biograhy: Thomas E. Keane Related Content: LATITUDE abstract from ASCO 2017 STAMPEDE abstract from ASCO 2017 STAMPEDE - Clinical Trial Information A Clinical Conversation with Alicia Morgans and Charles Ryan: Considerations of ASCO 2017 LATITUDE and STAMPEDE Crashing into progress: New findings meet old habits
|
- Details
- Clinical Considerations of ASCO 2017 relating to LATITUDE and STAMPEDE Biographies: Alicia Morgans, MD, MPH Charles J. Ryan, MD Related Content: LATITUDE abstract from ASCO 2017 STAMPEDE abstract from ASCO 2017 STAMPEDE - Clinical Trial Information Video Lecture on LATITUDE and STAMPEDE Trials
|
- Details
- Overall Survival Analysis of African Americans and Caucasian Patients Receiving Sipuleucel-T: Preliminary Data from the PROCEED Registry Read the Abstract Biographies: E. David Crawford Oliver Sartor is the only medical oncologist in Louisiana specializing in the treatment of prostate cancer patients. Dr. Sartor, the Laborde Professor of Cancer Research in the Medicine and Urology Departments of T...
|
